NCT03190577View on ClinicalTrials.gov

Assessment of the Prevalence of TTR Amyloid Neuropathy in a Population of Patients With Neuropathy of Unknown Aetiology

NACompletedINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

September 21, 2017

Primary Completion Date

May 23, 2022

Study Completion Date

May 23, 2022

Conditions
Familial Amyloid NeuropathyTransthyretin Amyloidosis
Interventions
GENETIC

blood sample

two 5 ML EDTA tubes of blood will be collected once by patient

Trial Locations (12)

17019

Ch La Rochelle, La Rochelle

22000

Ch Saint Brieuc, Saint-Brieuc

29107

Ch Quimper, Quimper

29609

Chru Brest, Brest

35760

CHP Saint-Grégoire - Cabinet de Neurologie ENMG, Saint-Grégoire

37044

Chru Tours, Tours

44606

Ch Saint Nazaire, Saint-Nazaire

49000

Chu Angers, Angers

72033

Ch Le Mans, Le Mans

85000

Chd La Roche Sur Yon, La Roche-sur-Yon

86021

Chu Poitiers, Poitiers

Unknown

Chu Nantes, Nantes

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Nantes University Hospital

OTHER

NCT03190577 - Assessment of the Prevalence of TTR Amyloid Neuropathy in a Population of Patients With Neuropathy of Unknown Aetiology | Biotech Hunter | Biotech Hunter